# Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy

> **NCT03309462** · NA · COMPLETED · sponsor: **Shanghai Chest Hospital** · enrollment: 50 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DEVICE:** Miseq sequencer

## Key facts

- **NCT ID:** NCT03309462
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-01
- **Primary completion:** 2018-06-30
- **Final completion:** 2019-07-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03309462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03309462, "Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03309462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*